Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 21:12:1543-1553.
doi: 10.2147/DMSO.S219013. eCollection 2019.

Therapeutic targets of hypercholesterolemia: HMGCR and LDLR

Shizhan Ma  1   2 , Wenxiu Sun  3 , Ling Gao  1   4   5 , Shudong Liu  6
Affiliations

Therapeutic targets of hypercholesterolemia: HMGCR and LDLR

Shizhan Ma et al. Diabetes Metab Syndr Obes. .

Abstract

Cholesterol homeostasis is critical and necessary for the body's functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low-density lipoprotein cholesterol receptor (LDLR) are major points of control in cholesterol homeostasis. We summarize the regulatory mechanisms of HMGCR and LDLR, which may provide insight for new drug design and development.

Keywords: CVD; HMGCR; LDLR; cholesterol homeostasis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Schematic diagram of cholesterol metabolic pathway in the body.
Figure 2
Figure 2
Control point of HMGCR. Abbreviations: HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; SRE, Sterol regulatory element; ER, endoplasmic reticulum; SREBP, sterol regulatory element binding protein; SCAP, SREBP cleavage activating protein; AMPK, AMP-activated protein kinase; PKC, Protein kinase C; CaMK, Ca2+/calmodulin-dependent protein kinase; ERAD, ER-associated degradation; 25-OH cholesterol, 25-hydroxycholesterol; RNF145, ring finger protein 145.
Figure 3
Figure 3
Control point of LDLR. Abbreviations: LDLR, low–density lipoprotein cholesterol receptor; SREBP, sterol regulatory element binding protein; IDOL, inducible degrader of the LDLR; PCSK9, proprotein convertase subtilisin/kexin type 9; LXR, Liver X receptors; R1, repeat 1 sequence; R2, repeat 2 sequence; R3, repeat 3 sequence; ERα, estrogen receptor α.
Figure 4
Figure 4
Schematic diagram of the hypercholesterolemia and current therapeutic drug. PCSK9 inhibitor: proprotein convertase subtilisin/kexin type 9 inhibitor. Abbreviations: LDL, low–density lipoprotein; LDLR, low–density lipoprotein cholesterol receptor.
See this image and copyright information in PMC

References

    1. Mazein A, Watterson S, Gibbs HC, et al. Regulation and feedback of cholesterol metabolism. Nature Precedings. 2011;59(2):473–474.
    1. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004;25(6):947–970. doi: 10.1210/er.2003-0030 - DOI - PubMed
    1. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137–174. doi: 10.1146/annurev.biochem.72.121801.161712 - DOI - PubMed
    1. Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010;10(1):16–21. - PMC - PubMed
    1. Garrido-Maraver J, Cordero MD, Oropesa-Avila M, et al. Coenzyme q10 therapy. Mol Syndromol. 2014;5(3–4):187–197. doi: 10.1159/000360101 - DOI - PMC - PubMed